Crucell Revenue
Biotechnology Research • 
Netherlands • 51-100 Employees
Crucell revenue & valuation
| Annual revenue | $382,200,000 |
| Revenue per employee | $3,822,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,223,000,000 |
| Total funding | $443,000,000 |
Key Contacts at Crucell
Wolfram Schlimme
Senior Director Regulatory Affairs
Richard Williams
Senior Director Cmc
Maria Pau
Senior Program Director Vaccines
Anna Renglin-Lindh
Director Early Stage Development, Crucell Leiden
Talent Acquisition Johnson & Johnson
Hr Director
Mohamed Ajoeb Idoe
Pd Director External Manufacturing
Chris Yallop
Director Protein Expression
Wendy He
Ra Director
Georg Burkard
Project Director
Company overview
| Headquarters | Netherlands |
| Phone number | +31715199100 |
| Website | |
| NAICS | 541714 |
| Keywords | R&D, Vaccines, Infectious Disease, Antibody |
| Employees | 51-100 |
| Socials |
Crucell Email Formats
Crucell uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 48.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 48.2% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 24.1% |
{first name}@company.com | john@company.com | 12.4% |
{last name}.{first name}@company.com | doe.john@company.com | 8.9% |
{first name}{last name}@company.com | johndoe@company.com | 6.4% |
About Crucell
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge. Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology. Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields. We are the largest independent vaccine company in the world. The combination of our innovative technologies and creative minds drives Crucell’s success, which we measure in human and business terms. Headquartered in Leiden, the Netherlands, Crucell currently employs over 1300 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam. Crucell N.V. is listed on NYSE Euronext and NASDAQ (CRXL) and the SIX Swiss Exchange (CRX).
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Crucell has 37 employees across 9 departments.
Departments
Number of employees
Canada
Germany
United States
SpainFrequently asked questions
4.8
40,000 users
